Tema Oncology ETF (NASDAQ:CANC) Short Interest Up 175.0% in November

Tema Oncology ETF (NASDAQ:CANC) was the target of a large growth in short interest in November. As of November 30th, there was short interest totalling 2,200 shares, a growth of 175.0% from the November 15th total of 800 shares. Based on an average daily volume of 2,800 shares, the days-to-cover ratio is currently 0.8 days.

Hedge Funds Weigh In On Tema Oncology ETF

An institutional investor recently bought a new position in Tema Oncology ETF stock. Thrivent Financial for Lutherans bought a new position in Tema Oncology ETF (NASDAQ:CANC) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 319,376 shares of the company’s stock, valued at approximately $8,616,000. Thrivent Financial for Lutherans owned 19.01% of Tema Oncology ETF at the end of the most recent reporting period.

Tema Oncology ETF Stock Performance

Shares of CANC traded down $0.84 during trading hours on Wednesday, hitting $26.25. 2,420 shares of the company were exchanged, compared to its average volume of 6,477. The company has a market cap of $45.68 million, a PE ratio of 26.86 and a beta of 1.11. The firm’s 50 day moving average is $27.76 and its 200-day moving average is $28.12. Tema Oncology ETF has a 52 week low of $24.77 and a 52 week high of $30.11.

About Tema Oncology ETF

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.